

## QIBA PET Myocardial Blood Flow (MBF) Biomarker Committee (BC)

Monday, May 10, 2021 at 9 am CT

### Call Summary

#### In attendance

*Robert deKemp, PhD (Co-Chair)*

*Marcelo di Carli, MD (Co-Chair)*

*Jonathan B. Moody, PhD (Co-Chair)*

P. David Mozley, MD

Nancy Obuchowski, PhD

#### RSNA Staff

Julie Lisiecki

**Moderator:** *Dr. deKemp*

#### Discussion

- BC members discussed preparing study level test-retest data for metanalysis
- Subject level estimates at rest and stress have been included from all studies
- There are up to 16 entries with reserve data available and a few studies with repeated analysis
- The raw data will be included
- Dr. Moody mentioned two studies had regional data where a non-standard method was used
  - These studies will be excluded as there is large variability between test-retest scans, and the stress wCV was 22%
- Most variability in regional data comes from different timepoints, erring on the side of positive bias
  - No same-day regional observations were available
- Dr. Obuchowski recommended keeping everything that might be useful, as well as providing a rationale for why any data should be excluded
  - Data in question can then be excluded to see how results are affected
  - The data have been updated in Dropbox
  - Dr. Moody to email the latest spreadsheet to Dr. Obuchowski
    - Dr. Obuchowski would like to know how the rest and stress data are being distinguished
- Dr. Moody to determine the 3 - 5 most important factors in the day-to-day vs. same-day data and adjust for the most important factors
- Dr. Obuchowski to conduct two analyses for subject level data (day-to-day and same day) and will add a predictor in the model
  - A difference is only expected between day-to-day and same day data
- Dr. Mozley suggested that systems variance should be assessed for the following:
  - No obvious disease
  - No obvious drug
  - Difference between rest and stress
- The two measurands, flow-reserve and stress, are the most clinically relevant
  - If results from the two are very different, separate models can be created
- Based on the discussion, the team feels more confident about drafting claims once a good estimate of wCV values is available
- Dr. Obuchowski suggested testing a few more items prior to finalizing the wCV to determine if the wCV and standard deviation are constant

**Action item:** Dr. Moody to provide Dr. Obuchowski with the updated Excel file of subject level data

**Next Call:** **May 24, 2021 at 9 am CT** (2<sup>nd</sup> and 4<sup>th</sup> Mondays) at 9 am CT

---

Parties interested in joining the [QIBA LinkedIn](https://www.linkedin.com/company/rsna-qiba) page for QIBA updates should visit: <https://www.linkedin.com/company/rsna-qiba>

## Process Committee

- All Profile Editors are encouraged to join the QIBA Process Committee to learn about QIBA writing tips and processes and network with other Profile Editors to exchange best practices
- **QIBA Process Committee Leaders:** [Kevin O'Donnell, MASC](#) (Chair) | [Michael Boss, PhD](#) (Co-Chair)
- **Wiki Resources:** [Dashboard](#) | [Profiles](#) | [QIBA Profile template](#) | [How to Write a QIBA Profile](#) | [Claim Guidance](#)
- **Inventory of QIBA tools:** [QIBA LinkedIn page](#) (please join / follow) | [QIBA News](#) | [QIBA Community](#)
- **Other:** [QIBA Webpage](#) | [QIBA Wiki](#) | [QIBA Biomarker Committees](#) | [QIBA Organization Chart](#) | [Dropbox](#)
- **EndNote:** To obtain access to the RSNA EndNote citations, please email: [sstanfa@rsna.org](mailto:sstanfa@rsna.org).